Fairmount Funds Management LLC
董事
Fairmount Funds Management LLC is a Philadelphia-based registered investment adviser specializing in biotechnology and life sciences, with a focus on promising new therapies, differentiated therapeutics, and companies with robust research and experienced management.[[1]](https://rocketreach.co/fairmount-funds-management-llc-profile_b43dbb07c19c9c58)[[2]](https://www.zoominfo.com/c/fairmount-funds-management-llc/398223033)[[3]](https://fairmountfunds.com) Headquartered in Conshohocken, Pennsylvania (with some sources listing Philadelphia addresses), the firm manages over $1 billion in assets under management (AUM), reported as high as $2.5B+ in some profiles and $1.11B in recent SEC 13F filings as of Q3 2025, employing around 21-26 staff and generating approximately $3 million in annual revenue.[[1]](https://rocketreach.co/fairmount-funds-management-llc-profile_b43dbb07c19c9c58)[[4]](https://whalewisdom.com/filer/fairmount-funds-management-llc)[[5]](https://fintel.io/i/fairmount-funds-management-llc)
Fairmount Funds invests in innovative biotech firms, as evidenced by its top holdings including Apogee Therapeutics (11.53%), Axsome Therapeutics (11.02%), and Enliven Therapeutics (9.65%), alongside recent activity such as adding to its position in Crescent Biopharma, Inc. (CBIO) (2.9% portfolio change, holding 16.50 million shares valued at $1.48M as of Q3 2025).[[4]](https://whalewisdom.com/filer/fairmount-funds-management-llc)[[5]](https://fintel.io/i/fairmount-funds-management-llc) As a hedge fund with 3 clients, it files as a corporate insider (e.g., Dir, 10% ownership in CBIO), supporting groundbreaking healthcare technologies through tailored investment strategies.[[1]](https://rocketreach.co/fairmount-funds-management-llc-profile_b43dbb07c19c9c58)[[2]](https://www.zoominfo.com/c/fairmount-funds-management-llc/398223033)[[4]](https://whalewisdom.com/filer/fairmount-funds-management-llc)
查看完整内部人档案 →